SOX9 and endometriosis: Animal studies have shown that, CMPD1 is a potent, selective, orally active GnRH antagonist that may have potential application as a therapeutic agent for treating hormone-dependent cancers and diseases including endometriosis [58].Other novel therapiesAromatase inhibitors have almost graduated from the pantheon of potential future therapies for endometriosis and they are now considered an acceptable therapy for endometriosis that does not respond to conventional treatments since they have shown promising preliminary results [59].